Pörssitiedote23.07.2024 klo 09.30Cyxone: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
Lehdistötiedote20.11.2023 klo 10.22Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor
Pörssitiedote09.10.2023 klo 09.38Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K
Pörssitiedote29.08.2023 klo 20.03Cyxone revises strategy for commercial alignment targeting valuable market opportunities
Lehdistötiedote31.05.2023 klo 15.00Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K